Orchestra BioMed Secures $110M in Financing with Guidance from Paul Hastings
Deal News | Aug 04, 2025 | Paul Hastings
Paul Hastings LLP has provided legal counsel to Orchestra BioMed in multiple financing transactions, including an underwritten public offering of common stock, alongside concurrent private placement and royalty financing transactions. This financial strategy is expected to generate over $110 million in gross proceeds for Orchestra BioMed, as they continue to bring advanced biomedical technologies to market through innovative partnerships. The joint book-running managers for the offering were Piper Sandler and TD Cowen.
Sectors
- Biomedical
- Legal Services
- Investment Banking
Geography
- United States – The involved companies and legal firms, such as Orchestra BioMed, Paul Hastings, Piper Sandler, TD Cowen, Ligand Pharmaceuticals, and Medtronic, are based in the United States, making it a relevant geography for the article.
Industry
- Biomedical – Orchestra BioMed operates in the biomedical industry, focusing on advancing high-impact medical technologies.
- Legal Services – Paul Hastings LLP provides legal advisory services, crucial in structuring and executing the financial transactions for Orchestra BioMed.
- Investment Banking – Piper Sandler and TD Cowen acted as joint book-running managers, underscoring the role of investment banking in orchestrating the public offering.
Financials
- 110 million USD – The expected gross proceeds from the financing transactions conducted by Orchestra BioMed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Orchestra BioMed | Target Company | Company | A biomedical company that accelerates high-impact technologies to patients through risk-reward sharing partnerships. |
| Paul Hastings LLP | Legal Advisor | Company | A prominent law firm providing legal counsel for the financing transactions of Orchestra BioMed. |
| Piper Sandler | Joint Book-running Manager | Company | An investment bank that managed the underwritten public offering for Orchestra BioMed. |
| TD Cowen | Joint Book-running Manager | Company | An investment bank involved in managing Orchestra BioMed's public offering alongside Piper Sandler. |
| Ligand Pharmaceuticals Incorporated | Investor | Company | Participated in the royalty financing transactions with Orchestra BioMed. |
| Medtronic Inc. | Investor | Company | Engaged in the royalty financing transactions with Orchestra BioMed. |